 A detailed analysis of ongoing, biomarker-based clinical trials initiated by big pharmaceutical companies.
 An analysis of the landscape of companies offering testing services for cancer biomarkers, namely TMB, MSI / MMR and TILs (including CD3+, CD4+, CD8+ and FOXP3+).
 An insightful 2X2 representation of the results of a detailed competitiveness analysis of various tests (segregated across different biomarker groups).

Leave a Reply